Malignant hyperthermia.
Malignant hyperthermia, a rapidly progressive, frequently lethal syndrome was not described until quite recently. Although treatment with the drug dantrolene has changed its face, a clear understanding and deep respect for the syndrome are necessary to keep fatalities and tragic sequelae to a minimum. The etiology and pathophysiology, preanesthetic diagnosis, incidence, management of the acute crisis, and anesthesia for susceptible patients are discussed, and a successfully treated fulminant case is analyzed.
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000503:physiopathology; D001706:Biopsy; D002118:Calcium / Q000032:analysis / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003402:Creatine Kinase / Q000097:blood; D003620:Dantrolene / Q000627:therapeutic use; D004562:Electrocardiography; D004576:Electromyography; D006801:Humans; D008297:Male; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D008991:Monitoring, Physiologic; D009127:Muscle Rigidity / Q000209:etiology; D010102:Oxygen Inhalation Therapy; D012737:Sex Factors; D013390:Succinylcholine / Q000009:adverse effects
D003402:Creatine Kinase; D003620:Dantrolene; D013390:Succinylcholine; D002118:Calcium